Janssen has published a report revealing significant gaps in understanding of blood cancer in individuals in China and Japan, calling for action to improve awareness about the disease in th
Novartis and Gilead’s CAR-T therapies have been approved in Europe – and the UK’s NICE immediately slapped down the latter, saying it is too expensive for regular NHS use in England and Wal
England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL)
